Please assess the completion status of the following clinical trial:

Trial Title: General Anesthesia With Xenon in Inspiratory Concentrations of 50% and 70% and Total I.V. Anaesthesia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient ≥ 50 years old~* ASA (American Society of Anaesthesiologists) Physical Status III~* Patient with increased risk of perioperative cardiac complications (Revised Cardiac Risk Index\>=2)~* Surgical operation: laparotomy or orthopaedic surgery or laparoscopy~* Planned duration of general anaesthesia in the range of 2-6 hours~* Patient willing and able to complete the requirements of this study including the signature of the written informed consent~Exclusion Criteria:~* Patient with severe impairment of cardiac function (Left Ventricular Ejection Fraction \< 35%)~* Patient with drug-eluting stent placed within 12 months prior to selection~* Woman of child-bearing potential not implementing adequate contraceptive methods~* Pregnant or lactating woman~* Surgical procedure in emergency~* Chronic opioids pain therapy~* Serious illness or medical conditions which are possible contra indication for elective general anaesthesia or administration of intra operative treatments, or which are interfering with the monitoring devices, such as:~  * Myocardial infarction within 6 months prior to selection~ * Any significant history of allergy/hypersensitivity to any drugs used during the study, to silicone or to latex~ * Severely impaired hearing~ * Known severe neurological disorders~ * Any medical condition which does not justify the trial participation in the investigator's judgement~ * General anaesthesia within 7 days prior to selection~ * Laparotomy within 3 months prior to selection, only for patients undergoing laparotomy~* History of drug abuse or psychiatric disorders which would impair the understanding of the necessary information or render medically or legally not able to give written informed consent~* Concurrent treatment with any other experimental drugs~* Participation in any other clinical trial within 4 weeks prior to selection

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Xenon 50% (45%-55%) in Oxygen (45%-55%),
- Group B (Type: EXPERIMENTAL): Xenon 70% (65%-75%) in Oxygen (25%-35%)
- Group C (Type: ACTIVE_COMPARATOR): Medical Air in Oxygen (45%-55%)

Based on this trial design, predict the completion outcome and termination type (if applicable).